Investing in Tomorrow's Health

• - Founding Director of NCL
• - CIO of Ashberg Ltd
• - Director of funds distribution for NTGI
• - Director at HSBC Securities
• - Director at BoS Investments
• - Holds the IMC, IAQ and is an FCA Approved Person (CF1/CF30)
• - Board positions on various tech SMEs

- PA to the Chairman of London Newcastle
- PA and HR Assistant at Devon and Cornwall Housing Association
- PA to the founder of a Charity Mail Order business in West Cornwall

• - CIO for two technology focused, Family Offices
• - Selection and active Board Membership through to exit of several successful SMEs
• - Founder of high growth health and wellness business
• - EasyGroup new ventures business manager
• - Developer of UKs first reverse auction website
• - Holds an MBA from INSEAD

- 2 years working in Venture Capital covering multiple verticals, primarily Medical Technology and Life Sciences
- Previous work at the United Nations and the Chilean Foreign Office
- Consultant with Jaguar Land Rover
- MPhil in Management from the University of Cambridge
- MA, First Class from the University of St. Andrews

- Originally trained as doctor and a surgeon
- Previously - 3i Private Equity, Pangaea Investors
- Senior leadership and advisory roles in the life-sciences sector
- Regular lecturer at Cambridge, Imperial and Stanford
- Holds a degree in medicine, degree in law, master’s degree in Surgical Technology and MBA from London Business School

- Founder of a menopause business and community
- Holds degrees in Neuroscience (BSc Hon) and Finance (MSc)
- Previously in Corporate Finance, focusing on lifesciences and medical businesses
- Competitive athlete (2x European Junior Karate Champion)

Mr. O'Neill is an experienced entrepreneurial business owner and corporate executive.

Mr. O'Neill is President of Kent Life Science Fund II, US and a member of the Investment Committee of the Fund. Previously Mr. O'Neill was co-founder and Managing Partner of KOM Capital LLC, a $1.2Bn alternative asset management firm focused on the Life Sciences and early stage energy sectors. Concurrently Mr. O'Neill served as non-executive Chairman of CCF 2, a China focused pre-IPO private equity fund and also has served as non-executive Chairman of SilkRoad China Asset Management LLC, a Hong Kong, investment fund focused on Asian listed securities.

Previously Mr. O'Neill held senior positions as President & Founder, Stewart & Company, a listed institutional asset management firm; Metzler Bank, N.A. as Co-Head, Americas; Canadian Imperial Bank of Commerce ("CIBC") as Managing Director and Senior Vice President, US; and Pitney Bowes Corporation as Controller.
Mr. O'Neill is a graduate of Quinnipiac University and is a Certified Public Accountant (inactive).

• - CFO at Precision Medicine Catapult Ltd
• - Finance Director at Innovate UK (Managing £650M of government innovation funding).
• - Commercial Director at Firstpoint Healthcare
• - Senior Finance Manager at Vodafone
• - Financial Controller Northern Europe at FedEx

• - Chairman of Places for People
• - Chairman of London & Newcastle
• - Member of Octopus Healthcare Advisory Board
• - Chairman of Horizon Infrastructure Partners
• - Managing Director of PB Securities
• - MD Lombard Odier UK Broking business
• - MD Colliers International UK

• - Currently on the board of several technology SMEs including Starglass SA and Expo Technologies
• - Chairman of Coomtech Ltd
• - 30 years experience managing significant change for international industrial businesses
• - Formerly CEO of Delta plc
• - Formerly Managing Director of GKN Driveline worldwide
• - Has a track record for successfully managing investments through the complete cycle, from identification to exit

Director of the Sackler Institute of Pulmonary Pharmacology at King’s College London. Internationally recognized in the pharmacology of inflammatory and respiratory diseases, with over 250 scientific papers. He was the co-founder and former Chairman at Verona Pharma plc (AIM listed), a NED of Babraham Biotechnology, Peptinnovate, Prep Biopharma and Epiendo. He was awarded an OBE for “Services to Pharmacology” in the Queen’s Birthday Honors List in 2017.

Professor of Cancer Therapeutics at University of Kent and Visiting Professor at the Institute of Cancer Research. Previously worked at Onyx Pharmaceuticals developing therapeutic products including the CDK4 inhibitor project, which went onto deliver Ibrance® (Palbociclib). Reader in Cancer Therapeutics and Head of Biology for the CRUK Cancer Therapeutics Unit. Michelle currently has three cancer drugs in the clinic.

Martin is the MD of Medway Community Healthcare and Chairman of Albion Outlook, covering 3 regions and over 30,000 patients. Martin joined NHS Medway from Ashford Primary Care Trust. He has a long-standing career in health, which has involved roles in commissioning, primary care and operations.

Vice President and Chief Scientific Officer of Catalent. Julien has sat on multiple Boards and has held positions at Catalent as Vice President, Science and Technology, and before that led Catalent’s European softgel R&D team. He holds an engineering degree in physico-chemistry from the ENSI in Caen, France.

Chief Executive at Rutherford Appleton & Daresbury Lab, has holdings in ESRF, ILL and the Diamond Light Source. He is a non‐executive director of a number of companies including Bio‐Nano Consulting and sits on the advisory board of the British Library. Currently he is on the board of the Joint Information Services Committee responsible for the UK academic computing network and chairs their Support for Research Committee. He is also involved with a number of charities including acting as chair of INASP. He was a founder member of the European Strategy Forum for Research Infrastructures. He is also a fellow of Wolfson College, Oxford.

CEO Emteq, AI healthcare company. A serial entrepreneur with a successful exit, selling DNS Ltd, a cyber AI company to Dell Secureworks. Graeme has 25 years' experience in AI & High-Tech businesses. He holds a degree in Computer Science and Artificial Intelligence from Edinburgh University.